Sanofi
SAN
Classement en actions
#225
Sanofi is a global healthcare enterprise dedicated to the research,... Sanofi is a global healthcare enterprise dedicated to the research, development, manufacturing, and commercialization of therapeutic solutions across the United States, Europe, and other international markets. Its business is structured into three primary divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. The Pharmaceuticals segment delivers specialized treatments, encompassing human monoclonal antibodies and therapies for a range of conditions such as multiple sclerosis, neurological disorders, various inflammatory and immunological diseases, rare disorders, oncology, and rare blood conditions. This division also provides medications for diabetes, cardiovascular health, and a portfolio of established prescription drugs. Through its Vaccines division, Sanofi supplies crucial immunizations, including pediatric vaccines for diseases like poliomyelitis, pertussis, and Hib, alongside adult vaccines addressing influenza, booster needs, meningitis, and those required for travel or endemic regions. The Consumer Healthcare portfolio features over-the-counter remedies for common ailments such as allergies, coughs and colds, and pain relief. It also includes products for liver care, general physical and mental wellness, probiotics, digestive health, and nutritional support. Additionally, this segment offers personal care items like daily body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and powders for eczema. Sanofi maintains an active pipeline with numerous pharmaceutical products and vaccines currently undergoing various stages of development. The company has forged strategic alliances, including a collaboration with GlaxoSmithKline for the development of a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine aimed at advancing immunology and inflammation knowledge, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company operated as Sanofi-Aventis before rebranding to Sanofi in May 2011.
Prix de l'action
$83.84
Capitalisation boursière
$100.45B
Changement (1 jour)
1.48%
Changement (1 an)
-16.74%
Pays
FR
Échange Sanofi (SAN)
Catégorie
Healthcare
Ratio P/E pour Sanofi (SAN)
Ratio P/E au October 2026 TTM : 22.92
Selon les derniers rapports financiers et le cours de l'action de Sanofi, le ratio P/E actuel (TTM) est de 22.92. À la fin de l’année 2024, le P/E de l’entreprise était de 21.10.
Historique du ratio P/E pour Sanofi de 2001 à 2026
Ratio P/E à la fin de chaque année
| Année | Ratio P/E | Changez |
|---|---|---|
| 2026 (TTM) | 22.92 | 77.27% |
| 2025 | 12.93 | -38.74% |
| 2024 | 21.10 | 1.40% |
| 2023 | 20.81 | 54.85% |
| 2022 | 13.44 | -24.64% |
| 2021 | 17.83 | 122.16% |
| 2020 | 8.02 | -80.27% |
| 2019 | 40.67 | 85.62% |
| 2018 | 21.91 | 104.46% |
| 2017 | 10.72 | -48.99% |
| 2016 | 21.01 | -12.27% |
| 2015 | 23.95 | 5.61% |
| 2014 | 22.68 | -17.41% |
| 2013 | 27.46 | 42.49% |
| 2012 | 19.27 | 46.27% |
| 2011 | 13.18 | -8.09% |
| 2010 | 14.34 | 4.92% |
| 2009 | 13.66 | 65.17% |
| 2008 | 8.27 | -48.59% |
| 2007 | 16.09 | -32.21% |
| 2006 | 23.74 | -45.86% |
| 2005 | 43.84 | -317.87% |
| 2004 | -20.12 | -199.40% |
| 2003 | 20.24 | -15.94% |
| 2002 | 24.08 | -37.41% |
| 2001 | 38.47 | 0.00% |
Ratio P/E pour des entreprises similaires ou concurrentes
| Entreprise | P/E Ratio | Différence du P/E Ratio | Pays |
|---|---|---|---|
| 43.73 | 90.79% |
US
|
|
| 39.77 | 73.51% |
US
|
|
| 80.21 | 249.97% |
US
|
|
| 121.17 | 428.64% |
US
|
|
| 25.53 | 11.37% |
CH
|
Comment lire un P/E ratio ?
Le ratio Prix/Bénéfice (P/E Ratio) mesure la relation entre le cours de l'action d'une entreprise et ses bénéfices par action.
Un P/E bas mais positif indique une entreprise qui génère des bénéfices élevés par rapport à sa valorisation et qui pourrait être sous-évaluée. Un P/E négatif élevé (proche de 0) indique des pertes importantes.
Les entreprises avec un P/E supérieur à 30 ou négatif sont généralement considérées comme des "actions de croissance", ce qui signifie que les investisseurs s'attendent à ce qu'elles se développent ou deviennent rentables.
Les entreprises avec un P/E positif inférieur à 10 sont généralement considérées comme des "actions de valeur", car elles sont déjà très rentables mais avec peu de potentiel de croissance.